– A-005 was well tolerated and demonstrated ability to cross blood-brain barrier – – Maximal TYK2 inhibition achieved with favorable…
If approved, UX111 would be the first approved therapy in the U.S. for Sanfilippo Syndrome Type ANOVATO, Calif., Dec. 19,…
VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) a biopharmaceutical…
Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom’s MacroglobulinemiaSAN FRANCISCO, Dec. 19,…
If you are considering a natural over the counter Mounjaro alternative for 2025 - we have the top 3 options…
North American drug delivery development experts added to help guide Lexaria's strategic plans KELOWNA, BC / ACCESSWIRE / December 18,…
Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to…
Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the…
- Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials…
LAUSANNE, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class…